Sunday, 24 October 2021


BI partners with Tsinghua for immuno therapies

05 September 2018 | News

This collaboration is an initiative of Boehringer Ingelheim’s Research Beyond Borders (RBB) and Cancer Immunology and Immune Modulation Research Departments.

Image credit- xbiotech.com

Image credit- xbiotech.com

Boehringer Ingelheim (BI) and Tsinghua University in Beijing have announced a collaboration aiming to research and develop immunological therapies for infectious diseases. Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Centre for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases.

The collaboration brings together the leading expertise of Tsinghua University in infectious disease research and immunology with Boehringer Ingelheim’s experience in the development of novel therapies for patients suffering from diseases with high unmet medical need and its comprehensive research and development programs in cancer immunology and immune modulation.

This collaboration is an initiative of Boehringer Ingelheim’s Research Beyond Borders (RBB) and Cancer Immunology and Immune Modulation Research Departments. Immuno-infection is a new focus area for Boehringer Ingelheim’s RBB department, which also focuses on gene therapy, regenerative medicine and the role of the microbiome in human health and disease.

With the new collaboration, Boehringer Ingelheim further expands its activities in the growing biomedical innovation hot spot of China. By combining a focus on cutting-edge science with a long-term view, the company aspires to develop the next generation of medical breakthroughs to improve the lives of patients suffering from diseases with high unmet medical needs.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account